The world health organisation has recognised mutations in the IDH1/2 gene as integral in diagnosis and prognostication of gliomas. The mutation facilitates production of the oncometabolite 2-hydroxygluarate (2-HG). The direct mechanisms behind the production and accumulation of 2-HG are well known, however we are yet to understand its effect on prognosis. Although the focus of in vivo studies has been on detection of the 2-HG peak, it is often impeded by spectral overcrowding. Here we used an NMR metabolomics approach to assess metabolome-wide alterations in the presence of the mutation to seek additionally detectable changes in metabolites in these tumours.